JGC
ETNB

J. Goldman & Co’s 89bio ETNB Stock Holding History

J. Goldman & Co’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41,500
Closed -$641K – 376
2023
Q3 		$641K Buy
+41,500
New +$697K 0.02% 261
2023
Q2 		– Sell
-27,000
Closed -$411K – 409
2023
Q1 		$411K Buy
+27,000
New +$352K 0.02% 279

Other funds holding ETNB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

J. Goldman & Co's ETNB Position: Q3 2025 in Review

J. Goldman & Co sold out of 89bio (ETNB) in Q3 2025, closing a stake of 96,339 shares — an estimated $946K sold.

J. Goldman & Co first reported a position in ETNB in Q4 2022 and held it in 4 quarters. The position peaked at $1.04M in Q1 2025. 198 funds tracked by Wall St. Rank hold ETNB as of Q3 2025.

  • J. Goldman & Co reported no remaining 89bio position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 96,339 89bio shares in Q3 2025, an estimated $946K.
  • J. Goldman & Co first reported a position in 89bio in Q4 2022 and held it in 4 quarters.
  • J. Goldman & Co's 89bio position peaked at $1.04M in Q1 2025.
  • 198 funds tracked by Wall St. Rank held 89bio as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.